Today: 9 June 2026
AT&T stock today: T holds steady into New Year market holiday as traders eye Jan. 28 earnings
1 January 2026
2 mins read

AT&T stock today: T holds steady into New Year market holiday as traders eye Jan. 28 earnings

NEW YORK, January 1, 2026, 16:44 ET — Market closed

  • AT&T shares last closed up 0.12% at $24.84 in the year’s final session on Wednesday
  • Wall Street ended 2025’s last trading day lower in thin holiday volume
  • Next catalysts include AT&T’s Jan. 28 earnings and a mid-January jobs report

AT&T Inc. shares ended 2025 slightly higher in the last U.S. session on Wednesday, holding up as broader indexes slipped into the New Year holiday. The stock last closed up 0.12% at $24.84.

The quiet close matters because year-end trading was thin, which can exaggerate moves in big dividend payers such as AT&T as investors reset portfolios for 2026. Markets were closed on Thursday for New Year’s Day.

With liquidity low, price action late in the week often reflected positioning more than fresh corporate news. “I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters

On Wednesday, the S&P 500 fell 0.74% and the Nasdaq lost 0.76%, while the Dow ended down 0.63%, capping a strong year for U.S. equities despite a soft finish.

AT&T’s big telecom peers were mixed in the same session, with Verizon edging up about 0.1% and T-Mobile slipping roughly 0.4%. Comcast, a major cable and broadband competitor, fell about 0.2%.

Wall Street research has also been a cross-current heading into 2026, with several firms trimming price targets while keeping broadly constructive stances. Citigroup analyst Michael Rollins kept a Buy rating but lowered his target to $29, while Goldman Sachs analyst Michael Ng kept a Buy and cut his target to $29, Benzinga reported.

Morgan Stanley analyst Simon Flannery kept an Overweight rating — a bullish call meaning the bank expects the stock to outperform — but lowered his target to $30, Benzinga said. Wolfe Research analyst Peter Supino downgraded the stock to Peer Perform, a hold-equivalent rating, according to the same report.

A “price target” is an analyst’s estimate of where a stock could trade over the next 12 months, not a guarantee. In telecom, targets often move with expectations for cash generation, competition in wireless and broadband, and interest-rate sensitivity.

AT&T’s dividend remains a key support in that debate. The company said its board declared a quarterly dividend of $0.2775 per share, payable Feb. 2 to shareholders of record on Jan. 12.

Annualized, that payout is about $1.11 per share, which implies a yield around 4.5% based on Wednesday’s close — one reason the stock can trade like an income proxy when Treasury yields shift.

The next company-specific catalyst is AT&T’s fourth-quarter report. AT&T said it will release results before the New York Stock Exchange opens on Jan. 28 and host a conference call at 8:30 a.m. ET.

Before next session, traders will be watching rates and policy expectations alongside single-stock positioning. The Federal Reserve’s next scheduled policy meeting runs Jan. 27–28, landing the same day as AT&T’s earnings release.

Macro risk markers are close behind. The ISM manufacturing PMI is due Jan. 5, while the U.S. employment report for December 2025 is scheduled for Jan. 13, according to the Labor Department calendar.

Technically, traders are also watching the low-$24 area as near-term support and $26 as resistance, Benzinga reported. A break either way could draw in short-term flows in a stock that often trades on yield and broader risk appetite rather than headline-driven momentum.

For now, AT&T heads into the first session of 2026 with a familiar setup: a steady dividend story, an earnings date on the calendar, and a market backdrop still keyed to the path of interest rates.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Broadcom Stock Forecast 2026: Wall Street Sees $460 Target for AVGO as AI Growth Meets Margin Test
Next Story

Broadcom Stock Forecast 2026: Wall Street Sees $460 Target for AVGO as AI Growth Meets Margin Test

Go toTop